HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 136192526Erstellt: 4. November 2026
Chromate(2-), (4-((4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo)-3-hydroxy-1-naphthalenesulfonato(3-))(4-hydroxy-3-((2-methyl-4H-pyrazolo(1,5-a)benzimidazol-3-yl)azo)benzenesulfonamidato(2-))-, disodium
https://huagongshe.com/de/chemical/136192526
Identifikatoren & physikalische Daten
| CAS No. | 83732-90-5 |
|---|
| Summenformel | C36H30CrN10Na2O8S2+2 |
|---|
| Durchschnittliche Molmasse | 892,8 g/mol |
|---|
| Monoisotopische Masse | 892,088994 g/mol |
|---|
| SMILES | Cc1[nH]n2c(nc3ccccc32)c1N=Nc1cc(S(=N)(=O)O)ccc1O.Cc1nn(-c2ccccc2)c(O)c1N=Nc1c(O)cc(S(=O)(=O)O)c2ccccc12.[Cr].[Na+].[Na+] |
|---|
| InChIKey | UIKMPBLZWMGZNH-UHFFFAOYSA-N |
|---|
| PubChem CID | 136192526 |
|---|
| EC No. | 280-642-8 |
|---|
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 293 |
|---|
| H-Brücken-Donoren | 7 |
|---|
| H-Brücken-Akzeptoren | 15 |
|---|
| Frei drehbare Bindungen | 3 |
|---|
| Schwere Atome | 59 |
|---|
| Formalladung | 2 |
|---|
| Komplexität | 1.630 |
|---|
Sicherheit & Vorschriften
| Regulatorische Informationen | Chemical: Chromate(2-), [4-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-3-hydroxy-1-naphthalenesulfonato(3-)][4-hydroxy-3-[(2-methyl-4H-pyrazolo[1,5-a]benzimidazol-3-yl)azo]benzenesulfonamidato(2-)]-, disodiumChromate(2-), 4-(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo-3-hydroxy-1-naphthalenesulfonato(3-)4-hydroxy-3-(2-methyl-4H-pyrazolo1,5-abenzimidazol-3-yl)azobenzenesulfonamidato(2-)-, disodium: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right. |
|---|
| Weitere Sicherheitsinformationen | IMAP assessments - Chromate(2-), [4-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-3-hydroxy-1-naphthalenesulfonato(3-)][4-hydroxy-3-[(2-methyl-4H-pyrazolo[1,5-a]benzimidazol-3-yl)azo]benzenesulfonamidato(2-)]-, disodium: Human health tier I assessment |
|---|